Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Experts (May 12, 2023)
О С Левин(Russian Medical Academy of Continuous Professional Education), S. N. Yanishevskiy(Federal Almazov North-West Medical Research Centre), Е Е Васенина, I. A. Voznyuk(Immanuel Kant Baltic Federal University), Svetlana Khatkova(Ministry of Health of the Russian Federation), А Н Боголепова(Pirogov Russian National Research Medical University), Т.В. Докукина(RSPC MT), А. Yu. Emelin(S. M. Kirov Military Medical Academy), V. Yu. Lobzin, M A Yakushin(Moscow Regional Research Institute of Obstetrics and Gynecology), Gavrilova Si, E. А. Mkhitaryan(Pirogov Russian National Research Medical University), О. Н. Ткачева(Pirogov Russian National Research Medical University), С. Н. Иллариошкин(Research Center of Neurology)
Cited by 7
Related Papers
Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial
|The Lancet Neurology|2015|213
Clinical guidelines on frailty
|Russian Journal of Geriatric Medicine|2020|187
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
|Obesity and metabolism|2021|123
Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis
|Osteoporosis and Bone Diseases|2021|110
Efficacy and safety of abobotulinumtoxinA in spastic lower limb
|Neurology|2017|96